
Opinion|Videos|March 7, 2025
Optimizing BTK Inhibitor Treatment: Managing Adverse Effects and Adherence
Panelists discuss proactive measures that health care teams can implement to manage adverse events associated with Bruton tyrosine kinase (BTK) inhibitors, such as early monitoring, dose adjustments, and supportive care, while emphasizing the importance of patient education to improve adherence and ensure positive treatment outcomes.
Advertisement
Episodes in this series

- What proactive measures can health care teams implement to manage adverse events associated with BTK inhibitors, ensuring both treatment adherence and patient quality of life?
- How can oncologists better educate patients about BTK inhibitors to improve adherence and support positive treatment outcomes?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
2
It’s Time to Reimagine Reimbursement for CAR T-Cell Therapy
3
What ACA Subsidy Expiration Means for Coverage Costs, Employer Strategy, and ICHRAs: Q&A With Ben Light
4
Fee-for-Service Models Linked to Higher Odds of Low-Value Surgical Procedures
5
















































